COVAGEN
Covagen develops bispecific FynomAbs by fusing its human Fynomer binding proteins to antibodies, resulting in therapeutics with novel modes of action and enhanced efficacy in the treatment of inflammatory diseases and cancer. The ability to fuse Fynomers to multiple sites on an antibody allows Covagen to create FynomAbs with tailored architectures to maximize efficacy. Their goal is to access novel biology for each product candidate. Covagen’s lead FynomAb COVA322 is being developed for the t... reatment of inflammatory diseases such as rheumatoid arthritis and psoriatic arthritis. In October 2012 Covagen entered into a strategic research collaboration and license agreement with Mitsubishi Tanabe / TRL for the development of bispecific FynomAbs against target pairs selected by Mitsubishi Tanabe / TRL. Covagen was founded in 2007 as a spin-off company from ETH Zurich (Swiss Federal Institute of Technology). A strong syndicate of investors supports Covagen’s drug development programs including Novartis Venture Fund, Edmond de Rothschild Investment Partners, Gimv, Seroba Kernel Life Sciences, Ventech, Ascent Biomedical Venture Management, MP Healthcare Venture Management, and Baxter Ventures.
COVAGEN
Social Links:
Industry:
Biopharma Biotechnology Therapeutics
Founded:
2007-01-01
Address:
Schlieren, Zurich, Switzerland
Country:
Switzerland
Website Url:
http://www.covagen.com
Total Employee:
11+
Status:
Closed
Contact:
41 44 732 46 60
Total Funding:
106.63 M USD
Current Advisors List
Current Employees Featured
Founder
Investors List
Seroba Life Sciences
Seroba Life Sciences investment in Series B - Covagen
Baxter Ventures
Baxter Ventures investment in Series B - Covagen
Gimv
Gimv investment in Series B - Covagen
Ventech
Ventech investment in Series B - Covagen
Andera Partners
Andera Partners investment in Series B - Covagen
Novartis Venture Fund
Novartis Venture Fund investment in Series B - Covagen
MP Healthcare Venture Management
MP Healthcare Venture Management investment in Series B - Covagen
Ascent Biomedical Ventures
Ascent Biomedical Ventures investment in Series B - Covagen
Edmond de Rothschild Private Equity
Edmond de Rothschild Private Equity investment in Series B - Covagen
Ventech
Ventech investment in Series A - Covagen
More informations about "Covagen"
Covagen - Crunchbase Company Profile & Funding
Covagen develops bispecific FynomAbs by fusing its human Fynomer binding proteins to antibodies, resulting in therapeutics with novel modes of action and …See details»
Covagen AG | ETH Zurich - ETH Zürich
Covagen specializes in the development of multispecific protein therapeutics through the FynomAb® technology platform. In 2014, Cilag GmbH International, an affiliate of the Janssen …See details»
Covagen Company Profile 2025: Valuation, Investors, …
Covagen General Information Description. Operator of a biopharmaceutical company intended to focus on therapies for inflammatory diseases and cancer. The company develops a proprietary platform that genetically fuses Fynomer …See details»
Covagen AG - Zürich, Switzerland - bionity.com
Covagen develops next generation protein drugs for the treatment of inflammatory diseases and cancer by using its proprietary protein engineering technology, which has been developed at …See details»
Covagen AG - LinkedIn
Covagen AG | 311 followers on LinkedIn. ... Y17 M22, Life Science ETH/Uni. Winterthurerstrasse 190. Zurich, 8057. SwitzerlandSee details»
Covagen AG - Company Profile and News - Bloomberg Markets
Company profile page for Covagen AG including stock price, company news, executives, board members, and contact informationSee details»
Covagen - Company Profile - Tracxn
Feb 24, 2025 Covagen - Develops bispecific antibodies for the treatment of inflammatory diseases and cancer. Acquired by Cilag. Raised a total funding of $56.3M over 5 rounds from …See details»
Covagen - Products, Competitors, Financials, Employees, …
Covagen. Frequently Asked Questions (FAQ). When was Covagen founded? Covagen was founded in 2007. Where is Covagen's headquarters? Covagen's headquarters is located at …See details»
Janssen Affiliate Cilag GmbH International Acquires Covagen AG
Aug 27, 2014 Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced that it has acquired Covagen AG, a privately-held, …See details»
Covagen: Next-Generation Protein Drugs
Timeline. 2006. ETH spin-off founded by Dragan Grabulovski and Julian Bertschinger in Schlieren ; Venture Leader; Venture 1. and 2. Phase 2008. CTI Startup Label 2011. Ranked in Top 100; 2012. Ranked in Top 100; Strategic …See details»
Covagen, Special Immunotherapy from Zurich
Apr 22, 2016 Mission: Founded by Julian Bertschinger and Dragan Grabulovski in 2007 , Covagen is a spin-off company of ETH Zurich which was later acquired in 2014 by Cilag (an affiliate of the Janssen / J & J). By binding proteins to …See details»
Covagen - Contacts, Employees, Board Members, Advisors & Alumni
Organization. Covagen . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Highlights. Employee Profiles 2. Number of Board Member and Advisor …See details»
Covagen AG - Life-Sciences-Europe.com
Jan 8, 2007 Upcoming Events. VentureCon Bioeconomy 2025 München (Munich) Forum Labo 2025 Paris; Health Tech Hub Styria 2025 Graz; Nordic-American Healthcare Conference 2025 …See details»
Student-led startup Covagen snapped up by J&J - Nature
Oct 9, 2014 Cilag, an affiliate of Johnson & Johnson–owned Janssen Pharmaceuticals, has acquired Covagen, launched by two postdocs at ETH Zurich in 2007.See details»
J&J’s Janssen buys Covagen - BioPharma Dive
Aug 26, 2014 Dive Brief: Cilag GmbH International, a J&J/Janssen subsidiary, has purchased the privately held Swiss biotech Covagen for an undisclosed sum.; Covagen specializes in …See details»
J&J snaps up Covagen and its protein-antibody fusion platform
Aug 25, 2014 J&J was drawn in by Covagen's "FynomAb" platform, which spawned COVA322, a bispecific TNF/IL-17A inhibitor with anti-inflammatory potential. The Swiss biotech--which …See details»
Covagen gets up to $63M in VC round for multitargeted antibodies
Dec 9, 2013 Swiss biotech startup Covagen landed a new round of venture backing today that could reach up to $63 million, enough to cover a Phase II program for its lead anti …See details»
Create an organization and manage users
Sep 9, 2024 In the upper-right corner, click the drop-down next to the bell, and then click Create Organization. Choose the Name of the organization with care, as this name is associated with …See details»
Caroline Voagen Nelson
Caroline voagen nelson studio. enterSee details»
Code Ruth — Caroline Voagen Nelson
Animated documentary Code Ruth is a true love story about a Morse code instructor finding her path during WWII. The short film blends stop motion techniques, digital collage, and archival …See details»